Artivion Q1 revenue up 8.6% to $77.2M; net loss of $0.08 per share

ARTIVION, INC.

2022-Q1 EPS reported -$0.08 revenue$77,213,000

Revenue $77.2M, +8.6% GAAP YoY; constant currency growth 11.2% driven by aortic stent grafts (+34%) and On-X (+11%).
Net loss $3.4M ($0.08/share) vs $3.1M loss in Q1 2021; non-GAAP net income $1.1M ($0.03/share) vs $1.4M.
Asia Pacific constant currency revenue +39%; Latin America +93%. Pipeline progress: PROACT Mitral and PerClot FDA PMA expected in 2022.
FY 2022 constant currency revenue growth guidance reaffirmed at 9.0%-11.0%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.